Norges Bank Makes New $36.82 Million Investment in Haemonetics Corporation $HAE

by · The Markets Daily

Norges Bank bought a new stake in Haemonetics Corporation (NYSE:HAE – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 493,520 shares of the medical instruments supplier’s stock, valued at approximately $36,822,000. Norges Bank owned about 1.02% of Haemonetics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Parkside Financial Bank & Trust lifted its holdings in Haemonetics by 11.6% in the second quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock valued at $109,000 after acquiring an additional 152 shares during the last quarter. GAMMA Investing LLC increased its stake in Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 165 shares during the last quarter. Quarry LP raised its position in Haemonetics by 63.4% in the first quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 192 shares during the period. Verdence Capital Advisors LLC lifted its stake in shares of Haemonetics by 3.6% in the 2nd quarter. Verdence Capital Advisors LLC now owns 6,216 shares of the medical instruments supplier’s stock valued at $464,000 after purchasing an additional 214 shares during the last quarter. Finally, Retirement Systems of Alabama grew its holdings in shares of Haemonetics by 0.4% during the 2nd quarter. Retirement Systems of Alabama now owns 61,401 shares of the medical instruments supplier’s stock worth $4,581,000 after purchasing an additional 256 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Price Performance

Haemonetics stock opened at $83.98 on Monday. The company has a quick ratio of 1.03, a current ratio of 1.64 and a debt-to-equity ratio of 1.08. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $85.23. The firm has a market cap of $3.93 billion, a PE ratio of 24.56, a price-to-earnings-growth ratio of 1.51 and a beta of 0.29. The company’s 50 day moving average is $61.83 and its two-hundred day moving average is $63.78.

Haemonetics (NYSE:HAE – Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping the consensus estimate of $1.12 by $0.15. The business had revenue of $327.32 million during the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, research analysts expect that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Barrington Research boosted their price objective on shares of Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, November 7th. BTIG Research reissued a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research note on Friday, November 21st. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday. Needham & Company LLC boosted their target price on Haemonetics from $68.00 to $78.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Finally, Raymond James Financial restated an “outperform” rating and set a $90.00 price target on shares of Haemonetics in a research report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $79.70.

View Our Latest Stock Analysis on Haemonetics

Haemonetics Profile

(Free Report)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.

Featured Stories

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE – Free Report).